CG
QNCX icon

Cutler Group’s Quince Therapeutics QNCX Stock Holding History

Cutler Group’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-55
Closed -$41K – 5048
2022
Q3 		$41K Sell
55
-1
-2% -$381 ﹤0.01% 2045
2022
Q2 		$37K Hold
56
– – ﹤0.01% 2184
2022
Q1 		$19K Buy
56
+43
+331% +$58.5K ﹤0.01% 3104
2021
Q4 		$91K Hold
13
– – ﹤0.01% 1920
2021
Q3 		$154K Buy
+13
New +$207K 0.01% 1569

Other funds holding QNCX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cutler Group's QNCX Position: Q1 2023 in Review

Cutler Group sold out of Quince Therapeutics (QNCX) in Q1 2023, closing a stake of 26 shares — an estimated $3K sold.

Cutler Group first reported a position in QNCX in Q4 2021 and held it in 5 quarters. The position peaked at $89K in Q4 2021. 42 funds tracked by Wall St. Rank hold QNCX as of Q1 2023.

  • Cutler Group reported no remaining Quince Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 26 Quince Therapeutics shares in Q1 2023, an estimated $3K.
  • Cutler Group first reported a position in Quince Therapeutics in Q4 2021 and held it in 5 quarters.
  • Cutler Group's Quince Therapeutics position peaked at $89K in Q4 2021.
  • 42 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.